PMID- 23620865
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20130429
LR  - 20240222
IS  - 2234-1900 (Print)
IS  - 2234-3164 (Electronic)
IS  - 2234-1900 (Linking)
VI  - 31
IP  - 1
DP  - 2013 Mar
TI  - Hypofractionated three-dimensional conformal radiotherapy for medically 
      inoperable early stage non-small-cell lung cancer.
PG  - 18-24
LID - 10.3857/roj.2013.31.1.18 [doi]
AB  - PURPOSE: The purpose of this study was to assess the clinical outcomes of 
      hypofractionated radiotherapy (HFRT) with three-dimensional conformal technique 
      for medically inoperable patients with early stage non-small-cell lung cancer 
      (NSCLC) and to evaluate prognostic factors. MATERIALS AND METHODS: We performed a 
      retrospective review of 26 patients who underwent HFRT for early stage NSCLC 
      between September 2005 and August 2011. Only clinical stage T1-3N0 was included. 
      The median RT dose was 70 Gy (range, 60 to 72 Gy) and the median biologically 
      equivalent dose (BED) was 94.5 Gy (range, 78.0 to 100.8 Gy). In 84.6% of 
      patients, 4 Gy per fraction was used. Neoadjuvant chemotherapy with paclitaxel 
      and cisplatin was given to 2 of 26 patients. RESULTS: The median follow-up time 
      for surviving patients was 21 months (range, 13 to 49 months). The overall 
      response rate was 53.9%, and the initial local control rate was 100%. The median 
      survival duration was 27.8 months. Rates of 2-year overall survival, 
      progression-free survival (PFS), local control (LC), and locoregional-free 
      survival (LRFS) were 54.3%, 61.1%, 74.6%, and 61.9%, respectively. Multivariate 
      analysis showed that BED (>90 vs. </=90 Gy) was an independent prognostic factor 
      influencing PFS, LC, and LRFS. Severe toxicities over grade 3 were not observed. 
      CONCLUSION: Radical HFRT can yield satisfactory disease control with acceptable 
      rates of toxicities in medically inoperable patients with early stage NSCLC. HFRT 
      is a viable alternative for clinics and patients ineligible for stereotactic 
      ablative radiotherapy. BED over 90 Gy and 4 Gy per fraction might be appropriate 
      for HFRT.
FAU - Lee, Joo Ho
AU  - Lee JH
AD  - Department of Radiation Oncology, Seoul National University College of Medicine, 
      Seoul, Korea.
FAU - Wu, Hong-Gyun
AU  - Wu HG
FAU - Kim, Hak Jae
AU  - Kim HJ
FAU - Park, Charn Il
AU  - Park CI
FAU - Lee, Se-Hoon
AU  - Lee SH
FAU - Kim, Dong-Wan
AU  - Kim DW
FAU - Heo, Dae Seog
AU  - Heo DS
LA  - eng
PT  - Journal Article
DEP - 20130331
PL  - Korea (South)
TA  - Radiat Oncol J
JT  - Radiation oncology journal
JID - 101577577
PMC - PMC3633227
OTO - NOTNLM
OT  - Early stage
OT  - Hypofractionated radiotherapy
OT  - Medically inoperable
OT  - Non-small-cell lung cancer
COIS- No potential conflict of interest relevant to this article was reported.
EDAT- 2013/04/27 06:00
MHDA- 2013/04/27 06:01
PMCR- 2013/03/01
CRDT- 2013/04/27 06:00
PHST- 2012/11/06 00:00 [received]
PHST- 2012/12/26 00:00 [revised]
PHST- 2013/01/16 00:00 [accepted]
PHST- 2013/04/27 06:00 [entrez]
PHST- 2013/04/27 06:00 [pubmed]
PHST- 2013/04/27 06:01 [medline]
PHST- 2013/03/01 00:00 [pmc-release]
AID - 10.3857/roj.2013.31.1.18 [doi]
PST - ppublish
SO  - Radiat Oncol J. 2013 Mar;31(1):18-24. doi: 10.3857/roj.2013.31.1.18. Epub 2013 
      Mar 31.